An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures
| Autor: | Luciane Pinto Gaspar, Patrícia P.C.C. Neves, Renata Carvalho Pereira, Marcos da Silva Freire, Andrea A.M.V. Silva, Marta Cristina O. Souza, Andréa Nazaré Monteiro Rangel da Silva, Marlon Vicente da Silva, Anna M. Y. Yamamura, Elena Caride, Denise D.C.S. Matos, Miguel Angel de la O Herrera |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Virus Cultivation
Yellow fever vaccine Biology Antibodies Viral Microbiology Plaque reduction neutralization test Bioreactors Neutralization Tests Propiolactone Chlorocebus aethiops Yellow Fever medicine Animals Alum adjuvant Vero Cells Immunization Schedule Duck embryo vaccine Attenuated vaccine General Veterinary General Immunology and Microbiology Yellow fever Yellow Fever Vaccine Public Health Environmental and Occupational Health medicine.disease Virology Antibodies Neutralizing Survival Analysis Immunity Humoral Vaccination Mice Inbred C57BL Infectious Diseases Vaccines Inactivated Inactivated vaccine Molecular Medicine Yellow fever virus medicine.drug Disinfectants |
| Zdroj: | Vaccine. 33(35) |
| ISSN: | 1873-2518 |
| Popis: | Yellow fever is an acute infectious disease caused by prototype virus of the genus Flavivirus. It is endemic in Africa and South America where it represents a serious public health problem causing epidemics of hemorrhagic fever with mortality rates ranging from 20% to 50%. There is no available antiviral therapy and vaccination is the primary method of disease control. Although the attenuated vaccines for yellow fever show safety and efficacy it became necessary to develop a new yellow fever vaccine due to the occurrence of rare serious adverse events, which include visceral and neurotropic diseases. The new inactivated vaccine should be safer and effective as the existing attenuated one. In the present study, the immunogenicity of an inactivated 17DD vaccine in C57BL/6 mice was evaluated. The yellow fever virus was produced by cultivation of Vero cells in bioreactors, inactivated with β-propiolactone, and adsorbed to aluminum hydroxide (alum). Mice were inoculated with inactivated 17DD vaccine containing alum adjuvant and followed by intracerebral challenge with 17DD virus. The results showed that animals receiving 3 doses of the inactivated vaccine (2 μg/dose) with alum adjuvant had neutralizing antibody titers above the cut-off of PRNT50 (Plaque Reduction Neutralization Test). In addition, animals immunized with inactivated vaccine showed survival rate of 100% after the challenge as well as animals immunized with commercial attenuated 17DD vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect